Consensus recommendations for improving pancreatic cancer care in Europe: *The Bratislava Statement*

Work Package 8, iPAAC
WP8 ASSOCIATED PARTNERS

NIJZ - HNACIONALNI INSTITUT ZA JAVNO ZDRAVJE (Slovenia)

WIV-ISP - INSTITUT SCIENTIFIQUE DE SANTE PUBLIQUE (Belgium)

THL - TERVEYDEN JA HYVINVOIN LAITOS (Finland)

ISS - ISTITUTO SUPERIORE DI SANITA (Italy)

SAM - LIETUVOS RESPUBLIKOS SVEIKATOS APSAUGOS MINISTERIJA (Lithuania)

INSP - INSTITUTUL NATIONAL DE SANATATE PUBLICA (Romania)

IPHS - INSTITUT ZA ZASTITU ZDRAVLJA SRBIJE DR MILAN JOVANOVIC BATUT (Serbia)

ICO - INSTITUT CATALA D'ONCOLOGIA (Spain)

BMC SAS - BIOMEDICINSKE CENTRUM SLOVENSKEJ AKADEMIE VIED (Slovakia)
COLLABORATING PARTNERS & SUBCONTRACTORS

Collaborating partners

**Spain**: CIBERESP & CIBERONC networks of research

**UK**: The Health Policy Partnership ALL.CAN

**Belgium**: KCE - Belgian Health Care Knowledge Centre

Subcontractors

**ECPC** – European Cancer Patient Coalition

**ECCO** – European CanCer Organisation
Neglected cancers / pancreatic cancer: The Bratislava statement on pancreatic cancer care

The Bratislava Statement: consensus recommendations for improving pancreatic cancer care

A working group comprising scientific societies, patient associations, cancer plans, and other relevant European stakeholders was organised in Bratislava (16-17th September, 2019).
Neglected cancers / pancreatic cancer: The Bratislava statement on pancreatic cancer care

Participant organisations
Biomedicinske Centrum (Slovak Academy of Sciences)
Catalonian Cancer Plan (ICO) & University of Barcelona (UB)
European CanCer Organisation (ECCO)
European Cancer Patients Coalition (ECPC)
European Society of Medical Oncology (ESMO)
European SocieTy for Radiotherapy & Oncology (ESTRO)
European Society of Surgical Oncology (ESSO)
Pancreatic Cancer Europe
Institut National Du Cancer (INCA)
Istituto Superiore di Sanità (ISS) - IRCCS of Reggio Emilia
Belgian Cancer Plan

Supporting organisations
European Hospital and Healthcare Federation (HOPE)
Vilnius University Hospital Santaros Klinikos
METHODOLOGY AND CONSENSUS PROCESS

Task 8.1 (ISS)
Definition of neglected cancers and the core clinical variables to describe pancreatic cancer patients pathways

Task 8.2 (ICO)
Proposal of criteria for reorganisation of treatment delivery with other partners and patients representatives

Objective

Neglected cancers: a policy concept

Outcome

‘Neglected cancers’ definition:
✓ Non-rare cancers with moderate incidence (< 20 per 100,000 population) and a high mortality/incidence ratio with low survival

Systematic review of the evidence on existing strategies for improving access to expert care for patients with pancreatic cancer

The Bratislava Statement: consensus recommendations for improving pancreatic cancer care
16-17th September, 2019, Bratislava

Essential requirements for Quality Cancer Care in Pancreatic Cancer

Policy recommendations integrating the ECCO standards of care
‘Neglected cancers’. A review\(^1\) was of population-based data on the incidence, mortality, and survival in solid cancers, in order to create a definition/list of neglected cancers and quantify their health impact:

- non-rare cancers with moderate incidence (< 20 per 100,000 population)
- low survival (relative survival ≤ 40% at 1 year and ≤ 30% at 3 or 5 years after diagnosis), due to either biological aggressiveness, late diagnosis, or lack of effective treatments

- The list of neglected cancer includes tumours of the gallbladder and biliary tract, stomach, liver, brain, central nervous system, and pancreas. However, pancreatic cancer is the most representative, as it has the highest mortality/incidence ratio and the lowest survival at one, three and five years after diagnosis.

---

1. Innovation Partnership for Action Against Cancer (iPAAC) Joint Action. Definition of neglected cancers: the case for pancreatic cancer. Specific task 8.1, Work Package 8 of the iPAAC.
Figure 1: European mean age-standardised 5-year relative survival for adult patients with cancer diagnosed in 2000-2007.

Systematic review of the evidence on existing strategies and policy tools for improving access to expert care for patients with pancreatic cancer

We identified four overarching health policy strategies used alone or in combination to increase quality of care and patients’ access to specialised centres

41 papers included
THE BRATISLAVA STATEMENT: CONSENSUS RECOMMENDATIONS FOR IMPROVING PANCREATIC CANCER CARE

Innovative Partnership for Action Against Cancer (iPAAC) consensus group
Reorganisation of pancreatic cancer services and coordination of care

Internal structure of centres, care processes, and proven expertise

External assessment of quality and feedback performance systems

Research

The role of patient organisations, scientific societies and European stakeholders

22 statements were approved
The document circulated among participants and other stakeholders.
CONSENSUS RECOMMENDATIONS FOR IMPROVING PANCREATIC CANCER CARE

Reorganisation of pancreatic cancer services and coordination of care

- **Statement 1** - Implement integrated health care policies that promote specialisation and put expert MDTs at the centre of the decision-making process.

The complexity of managing and operating on pancreatic cancer, together with its relatively low incidence, justifies the consolidation of expertise within specialised MDTs or units. Such organisational changes are currently among the most effective interventions for improving patient outcomes and optimising the use of health care resources.
Reorganisation of pancreatic cancer services and coordination of care

• **Statement 2** - Identify reference centres and build around these efficient models of centralised care.

*While surgical outcomes and especially surgical volume (pancreatectomies/year) are the most frequently studied measure of quality of care in pancreatic cancer, only a minority of patients undergo resection. Therefore, when identifying the centres providing the best care, a range of other domains should be taken into account, including referral pathways, diagnostic procedures, indications for and administration of medical (systemic) treatments, early integration of palliative care, research output, and participation in clinical trials, among others.*
Reorganisation of pancreatic cancer services and coordination of care

• **Statement 3** - Shape national or regional care models to allow alignment with international quality criteria.

Rigorous quality criteria, whether developed by a single health system or adapted from international guidance, are a prerequisite for ensuring high-quality care and should lead to a redistribution of cases towards reference centres. ECCO Essential Requirements for Quality Cancer Care are one set of criteria that recognise the need for a multifaceted perspective, providing national and regional health authorities with a valuable tool to define the characteristics of reference centres.
Reorganisation of pancreatic cancer services and coordination of care

• **Statement 4** - Create policy levers to ensure the adherence of non-specialised providers to established referral pathways.

*Health care systems may utilise different mechanisms to endow expert multidisciplinary teams with the mandate to lead clinical decision-making processes (e.g. designation of providers, minimum surgical volumes, publication of surgical outcomes). However, poor adherence among non-specialised providers to optimal referral pathways can pose challenges to achieving system objectives. Different policy tools can favour effective change: establishing some degree of legal enforcement to consolidate such a policy; incorporating financial incentives and/or disincentives for the centres; and allowing a transition period before full adoption of the policy.*
Reorganisation of pancreatic cancer services and coordination of care

• **Statement 5** - Allocate enough resources to reference centres to support implementation of reorganisation strategies and facilitate an orderly transition of patients between institutions, regions and countries.

Designating reference centres in pancreatic cancer produces a net benefit for both patients (better outcomes) and health care systems (more efficient use of resources). However, redirecting patient flows to these centres can also increase the pressure to service providers and introduce geographical access barriers, resulting in patient selection biases, whereby certain patient groups – like those with better health or socioeconomic status – are most likely to have access to specialist care. This can increase the ‘financial toxicity’ of this cancer for patients. Moreover, newly designated pancreatic cancer care units may not have all the tools or training needed to rapidly align their practices with ever evolving state-of-the-art clinical practice guidelines. To fully take advantage of the potential benefits of this model, health care authorities should work to support reference centres to absorb the impacts that these organisational changes produce.
Reorganisation of pancreatic cancer services and coordination of care

• **Statement 6** - Create and/or strengthen networks between reference centres and other providers in order to improve continuity of care, circulation of knowledge and integration among professionals.

Even if most patients are referred to reference centres, non-specialised hospitals and other providers will continue to play an important role in the clinical management of some patients, for example those presenting to the outpatient clinics or emergency departments of non-reference centres without a confirmed diagnosis of pancreatic cancer, those experiencing tumour- or treatment-related complications, patients refusing referral (often due to old age or numerous comorbidities), and those who receive follow-up and after-care, including chemotherapy, close to home. Nurturing both formal and informal links between providers with different levels of specialisation can help to ensure better outcomes even for those who are managed in non-reference centres.
Reorganisation of pancreatic cancer services and coordination of care

• **Statement 7** - Articulate clinical services at all levels of the healthcare system through a network approach, by including primary care, palliative care (e.g. home care), and survivorship care, among others, in the organisational framework.

*The patient journey does not begin or end in a specialised MDT unit: early diagnosis, quality of care for patients who cannot undergo surgery, and the organisation of follow-up remain equally important challenges. Family doctors’ awareness and suspicion of pancreatic cancer is crucial for achieving early diagnosis and a subsequently better prognosis, and indeed, primary care has an important parallel role to specialist services throughout the treatment phase and beyond. Outpatient palliative care (e.g. home care, pain clinics), survivorship and rehabilitation services can likewise greatly improve patients’ quality of life. Incorporating supportive care early in the care process is of special importance. To facilitate the patient journey, a single health professional (such as a GP, nurse, or specialist) should be designated as a principal contact to help patients navigate different levels of care and ensure effective communication.*
Reinforcement of the internal structure of centres, care processes, and proven expertise

- **Statement 8** - Equip reference centres with appropriate infrastructures as well as material and technical resources to enable MDTs to effectively perform their mission.

Efficiently reorganising the internal structure of the centre and adopting quality care processes can affect patient outcomes more than merely increasing surgical volume. As laid out by ECCO, outcomes may be associated, for example, with expert tumour boards, highly specialised resources such as intensive care units and molecular pathology departments, and 24/7 on-call surgery and specialists (including interventional radiologists and endoscopists). Such internal structures also influence centres’ ability to anticipate and confidently manage acute and sometimes life-threatening complications.
Reinforcement of the internal structure of centres, care processes, and proven expertise

• **Statement 9** - Capitalize on the opportunities offered by reference centres for developing, accumulating, and applying expertise.

Centralised teams that manage highly complex diseases are the natural setting for developing professional skills. The experience acquired by providers in caring for patients with tumours such as pancreatic cancer — in terms of shared utilisation of technology and expert knowledge — could translate into a shared benefit, influencing the outcomes of patients with different profiles and enhancing the learning opportunities for health care professionals.
Reinforcement of the internal structure of centres, care processes, and proven expertise

• **Statement 10** - Staff MDT units with specialists from all disciplines who have a role in pancreatic cancer care.

The ECCO Essential Requirements for Quality Cancer Care initiative calls for specialised MDT units to include the core specialties of medical oncology, gastroenterology/endoscopy, pathology, radiology/interventional radiology, surgery, nuclear medicine, radiation oncology, nursing, and palliative care. An extended MDT should include professionals from fields such as anaesthesia/intensive care, geriatric oncology, nutrition, oncology pharmacy, psycho-oncology, physiotherapy, genetics, and rehabilitation and survivorship.
Reinforcement of the internal structure of centres, care processes, and proven expertise

- **Statement 11** - Consider implementing formal accreditation systems for centres and professionals.

Accrediting centres and professionals may have a significant impact on the reorganisation of health care services in cases where having multidisciplinary clinical units for hepatobiliarypancreatic diseases have been identified as a quality criterion. At the same time, professional accreditation of clinical competencies for specialists in pancreatic diseases is also a critical element from a European perspective. Standardising training to the point where expert knowledge and skills are equivalent across countries could facilitate professional exchange and mobility, and benefit geographic areas with scarce or inequitably concentrated expertise.
Implementation of external quality assessment and feedback performance systems

• **Statement 12** - Establish standardised electronic health records systems for pancreatic cancer and maintain high-quality cancer registries to generate and share real-world data.

*Standardised reporting with electronic health records can generate valuable epidemiological data. At the same time, cancer registries that include information on outcomes and/or quality measures related to pancreatic cancer are fundamental for illustrating the variability of clinical practice and understanding potential differences in quality between centres. Together, these systems can foster research, enhance transparency and help centres improve the quality of their services.*
Implementation of external quality assessment and feedback performance systems

• Statement 13 - Use external data assessment to inform organisational changes and quality improvement strategies.

Reference centres should be defined and monitored according to criteria defined at a system level. Evaluation may be based on external clinical audits, population-based cancer registries, clinical follow-up registries and national quality programmes, and these assessments can drive the reorganisation of health care systems and treatment centres, including in pancreatic cancer care. Feedback performance systems can complement the set of strategies described here.
Implementation of external quality assessment and feedback performance systems

• **Statement 14** - Determine and report performance indicators along with patient and surgical volumes, to increase transparency and facilitate decisions on treatment centres.

*Transparency around care quality and outcomes for providers treating patients with pancreatic cancer may factor into decisions about referral to the treatment centre or directly into patients’ preferences. Existing performance indicators, like surgical volume and outcomes, should be published, even as other indicators capturing information on other domains of care, should be developed and validated at a national level (e.g. by the cancer plan or health care system).*
Research

- **Statement 15** - Establish a research agenda for neglected cancers at the European level, using pancreatic cancer as the archetype.

*Prioritisation of this area of work by the European Commission should create ripple effects in member states, enabling advances in basic as well as epidemiological, genetic, translational, clinical, and health care services research. Indeed, only by supporting a comprehensive research agenda can the outcomes of neglected cancers truly improve. Participation by patient groups in shaping and planning this work will be fundamental in aligning knowledge generation with patient needs.*
Research

- **Statement 16** - Prioritise research streams and structures dedicated to prevention, risk prediction, early detection and diagnosis, and rapid referral for treatment.

Risk prediction, early diagnosis, and appropriate treatment indications in pancreatic cancer remain central challenges for improving survival outcomes. There are still large evidence gaps about which pancreatic lesions are pre-malignant, how high-risk groups should be defined and identified, which diagnostic tests are most accurate, and who would most benefit from screening. Likewise, there is an urgent need to articulate rapid referral pathways for patients presenting with ‘red flag’ symptoms in different contexts. Investments are needed in both data repositories (e.g. biobanks, tissue banks, health care services data) and in sustained research programmes.
• **Statement 17** - Foster the design of collaborative research programmes/platforms within reference centres.

*Designating reference centres at regional, national, and international level can facilitate these centres’ leadership in basic, clinical, and translational research as well as in professional training. Research programmes should be developed and carried through in collaboration with national and international partners, patient organisations, and other public and private partners with a special interest in pancreatic cancer, and in alignment with a European research agenda.*
CONSENSUS RECOMMENDATIONS FOR IMPROVING PANCREATIC CANCER CARE

Optimisation of the role of patient organisations, scientific societies and European stakeholders

• **Statement 18** - Engage patient organisations as equal partners in shaping policies based on a holistic vision of the patient journey, from clinical suspicion to diagnosis, treatment, palliation and survivor care.

Patients are the group with the most to gain from centralising care in highly specialised MDT units; however, they are not always informed of the potential for improved clinical and surgical outcomes nor consulted about how such changes would affect them. Empowering patients to play an active role in the reorganisation of care models can avert potential problems associated with logistics (transport, accommodation) and economic burdens related to treatment. Moreover, embedding their perspective in decisions about patient flows within and between care levels is the only way to achieve a truly patient-centred organisational model.
Optimisation of the role of patient organisations, scientific societies and European stakeholders

• **Statement 19** - Empower patient representatives to take ownership and leadership in public debates about optimisation of health care models.

*Policies denominated ‘centralisation strategies’ may not be well received by the public based on the concern that these would introduce limitations and discrimination in access to care. Because the most powerful advocates for patients are patients, survivors and their loved ones, patient groups are vital partners in building the political momentum necessary to implement evidence-based improvements. In order to do so, they need to be informed and actively involved in public debates.*
**Optimisation of the role of patient organisations, scientific societies and European stakeholders**

- **Statement 20** - Develop guidelines that can help health care systems align best practices in health care, health services organisation, and human resource development.

*Scientific societies are uniquely situated at the nexus of research, practice, and policy; moreover, their diverse membership ensures both depth and breadth to their expertise. These bodies can build on their experience developing clinical practice guidelines in order to set organisational specifications and define professional competencies, providing solid guidance for health care authorities, practitioners, and educational institutions.*
Optimisation of the role of patient organisations, scientific societies and European stakeholders

- **Statement 21** - Shape the policy environment in a way that favours investments in research and evidence-based care models.

This can include forming alliances and collaborations between major stakeholders, including patient organisations and scientific societies dedicated to improving neglected cancer care.
Optimisation of the role of patient organisations, scientific societies and European stakeholders

• **Statement 22** - Organise national and international awareness campaigns with a special focus on prevention and early diagnosis.

Awareness campaigns can serve a dual purpose in the field of pancreatic cancer: (a) fostering people’s recognition of risk factors and early signs and symptoms of the disease in order to favour better primary and secondary prevention, and (b) building public support for prioritising this disease at the health system level.
THE BRATISLAVA STATEMENT: CONSENSUS RECOMMENDATIONS FOR IMPROVING PANCREATIC CANCER CARE

Innovative Partnership for Action Against Cancer (iPAAC) consensus group

Discussion